Chief
National Cancer Center
Chuoku, Tokyo, Japan
Tadashi Kondo, M.D., Ph.D. is Chief of the Division of Rare Cancer Research at the National Cancer Center Research Institute (NCCRI), Japan, a role he has held since August 2014.
After graduating from medical school in 1992, Dr. Kondo began his research career in proteomics—a field that was still in its infancy at the time. In 2001, he joined the National Cancer Center, where he established Japan’s first dedicated laboratory for large-scale cancer proteomics. His early research focused on biomarker discovery for personalized medicine, which naturally led to a deeper engagement with cancer research.
In 2014, Dr. Kondo launched a new research division focused specifically on rare cancers. Recognizing the lack of appropriate experimental models as a major obstacle, he initiated a nationwide effort to develop and distribute patient-derived cancer models, including cell lines and xenografts. These models have become essential tools for drug development and biomarker discovery in Japan and internationally. He uses his model library to conduct the pharmaco-proteogenomics for rare cancers in the world-wide project.
Since 2024, he has expanded his work to include comparative oncology, investigating how cancer incidence varies across species. This approach aims to uncover evolutionarily conserved and species-specific mechanisms of tumorigenesis, with the goal of informing both human and veterinary oncology. One practical benefit is the ability to conduct trials in animals for rare human cancers that occur more frequently in other species.
These diverse experiences have shaped not only Dr. Kondo’s scientific focus but also his core philosophy: to conduct research that truly makes a difference—for patients, healthcare professionals, and future generations alike.
Paper 23 - JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS
Thursday, November 13, 2025
4:15 PM - 5:30 PM EST
Disclosure information not submitted.
